Coley's toxins in perspective
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Despite initial hopes, the efficacy of tumour necrosis factor in treating cancer patients has been disappointing. But a more careful selection of patients, and more appropriate treatment, might be fruitful.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, in certain cases, injection of intratumoral bacteria or their antigens may conversely provide immunostimulatory effects, as demonstrated by Coley’s toxins and recent developments in bacterial cancer therapy (5, 105, 106).”
From The microbiome and human cancer (2021) · cites this paper as [5]
Citations
Cites
An endotoxin-induced serum factor that causes necrosis of tumors
Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., & Williamson, B. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.9.3666 · Cited by 4,532
Goetz, F. (2004) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2003.09.008 · Cited by 301
Berendt, M. J., North, R. J., & Kirstein, D. P. (1978) · The Journal of Experimental Medicine · doi:10.1084/jem.148.6.1560 · Cited by 84
Prevalence of dysplasia and cancer of the cervix in a nationwide, planned parenthood population
Sadeghi, S. B., Sadeghi, A., & Robboy, S. J. (1988) · Cancer · doi:10.1002/1097-0142(19880601)61:11<2219::aid-cncr2820611116>3.0.co;2-d · Cited by 58
Demetri, G. D., Spriggs, D. R., Sherman, M., Arthur, K. A., Imamura, K., & Kufe, D. W. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.10.1545 · Cited by 57
Remarks upon the Effects Observed in the Use of Mixed Toxins (Coley) in Certain Cases of Sarcoma
Harmer, T. W. (1914) · New England Journal of Medicine · doi:10.1056/nejm191408131710701 · Cited by 4
Research works printed but not linked: 4
- Coley, W. B. Practitioner 83, 589–613 (1909).
- Nauts, H. C. et al. Can. Res. 6, 205–216 (1946).
- Tichatschek, E. et al. Can. Immun. Immunother. 27, 278–282 (1988).
- McIntosh, J. K. et al. Can. Res. 49, 1408–1414 (1989).
Cited by
Items 101–200 of 282
Of Flies and Men—The Discovery of TLRs
Weiss, H. J., & O'Neill, L. A. J. (2022) · Cells · doi:10.3390/cells11193127 · Cited by 36
“Coley started treating his cancer patients at the Memorial Hospital in New York with heat-inactivated bacteria, observing tumor remission in some cases [46], which, today, we know was due to the strong activation of the immune system by the bacterial LPS [47].”
BackgroundMuehleisen, B., Jiang, S. B., Gladsjo, J. A., Gerber, M., Hata, T. R., & Gallo, R. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040754 · Cited by 35
Hino, M., Kohchi, C., Nishizawa, T., Yoshida, A., Nakata, K., Inagawa, H., Hori, H., Makino, K., Terada, H., & Soma, G. (2005) · PubMed · Cited by 28
Redrawing therapeutic boundaries: microbiota and cancer
Sholl, J., Sepich‐Poore, G. D., Knight, R. D., & Pradeu, T. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.10.008 · Cited by 33
A combination of E. coli DNA fragments and modified lipopolysaccharides as a cancer immunotherapy
Cho, Y. J., Ahn, B. Y., Lee, N. G., Lee, D. H., & Kim, D. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.04.048 · Cited by 27
Implantable Biomaterials for Cancer Immunotherapies
Печникова, Н. А., Aggeli, A., Latypova, A., Iaremenko, A. V., Domvri, K., Zubarev, I. V., Chuang, L. I. U., & Yaremenko, A. V. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202416813 · Cited by 28
Krone, B., Kölmel, K. F., & Grange, J. M. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-595 · Cited by 25
“There have been several more studies on this topic [15-23], but the evidence for the effectiveness of this therapeutic approach remains disputed.”
BackgroundPlotnikoff, G. A. (2014) · Global Advances in Health and Medicine · doi:10.7453/gahmj.2014.021 · Cited by 23
“In this case, FXR activation results in multiple pro-cancer effects relevant to breast health including: (1) estrogen-receptor activation, 42,43 (2) promotion of cancer cell survival,44 (3) induced migration of metastatic human breast cancer MDA-MB-231 cells45 and (4) expression of drug resistance proteins.”
BackgroundThe role of cellular proteostasis in antitumor immunity
Mercier, R., & LaPointe, P. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101930 · Cited by 27
Potential therapeutic anti-tumor effect of aSalmonella-based vaccine
Chang, S., Kim, Y., & Ko, H. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.24917 · Cited by 22
Immunotherapy of Malignant Gliomas Using Autologous and Allogeneic Tissue Cells
Hofman, F. M., Stathopoulos, A., Kruse, C. A., Chen, T. C., & Schijns, V. E. J. C. (2010) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520611009060462 · Cited by 24
“Coley, an early 20th century New York City surgeon, observed that some of his patients with sarcoma would undergo spontaneous regression of their tumor and that this regression was associated with antecedent bacterial infection (erysipelas, or streptococcus pyogenes in the first patient) which eliminated malignant cel…”
BackgroundImmunomodulation therapy in colorectal carcinoma
Yip, D., Strickland, A. H., Karapetis, C. S., Hawkins, C. A., & Harper, P. (2000) · Cancer Treatment Reviews · doi:10.1053/ctrv.1999.0160 · Cited by 23
Characterization of a streptococcal antitumor glycoprotein (SAGP)
Yoshida, J., Takamura, S., & Nishio, M. (1998) · Life Sciences · doi:10.1016/s0024-3205(97)01142-9 · Cited by 22
How does the gut microbiome influence immune checkpoint blockade therapy?
Almonte, A. A., Rangarajan, H., Yip, D., & Fahrer, A. M. (2021) · Immunology & Cell Biology · doi:10.1111/imcb.12423 · Cited by 21
“William Coley, the “Father of Immunotherapy,” successfully performed intravenous and intratumoral injections with a mixture of Streptococcus pyogenes and Serratia marcescens to acheive impressive regression rates.(58,59) Intravesical administration of live Bacillus Calmette–Gu erin has been one of the most successful…”
BackgroundQiao, Y., Luo, M., Wang, Y., Qi, H., Wang, M., Pei, Y., Sun, M., Zhang, Z., Huang, J., Gong, P., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.07.020 · Cited by 21
Enhanced immunostimulatory activity of in silico discovered agonists of Toll-like receptor 2 (TLR2)
Murgueitio, M. S., Ebner, S., Hörtnagl, P., Rakers, C., Bruckner, R. S., Henneke, P., Wolber, G., & Santos‐Sierra, S. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.07.011 · Cited by 21
Reticker-Flynn, N. E., & Engleman, E. G. (2020) · eLife · doi:10.7554/elife.53839 · Cited by 26
Schliemann, C., Hemmerle, T., Berdel, A. F., Angenendt, L., Kerkhoff, A., Hering, J. P., Heindel, W. L., Hartmann, W., Wardelmann, E., Chawla, S. P., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.038 · Cited by 21
Gurunathan, S., Ajmani, A., & Kim, J. (2023) · Microbial Pathogenesis · doi:10.1016/j.micpath.2023.106396 · Cited by 21
Wang, H., Chen, T., Wan, L., Lu, J., Wei, H., Deng, K., Wei, J., & Xin, H. (2020) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-020-10485-3 · Cited by 20
“Immunotherapy and bacterial treatment came on stage by coincidence when Doctor Coley injected Streptococcus into cancer patients and successfully treated tumors more than 100 years ago with unknown mechanism at that time (Orange et al. 2016; Starnes 1992).”
BackgroundEndotoxemia in Healthy Subjects as a Human Model of Inflammation
van der Poll, T., & van Deventer, S. J. H. (2002) · Springer eBooks · doi:10.1007/978-3-642-57210-4_22 · Cited by 22
Rook, G. A. W. (1992) · Nature · doi:10.1038/357545a0 · Cited by 21
Xu, P., Zhang, X., Chen, K., Zhu, M., Jia, R., Zhou, Q., Yang, J., Dai, J., Jin, Y., & Shi, K. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0595 · Cited by 20
Corbellari, R., Nadal, L., Villa, A., Neri, D., & Luca, R. D. (2020) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000938 · Cited by 19
Clinical Translation of Inorganic Nanoparticles and Engineered Living Materials for Cancer Therapy
Gandarias, L., & Faivre, D. (2024) · ChemPlusChem · doi:10.1002/cplu.202400090 · Cited by 20
Salmonella cancer therapy metabolically disrupts tumours at the collateral cost of T cell immunity
Copland, A., Mackie, G. M., Scarfe, L., Jinks, E., Lecky, D. A. J., Gudgeon, N. H., McQuade, R., Lab), M. O. (., Barthel, M., Hardt, W., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00159-2 · Cited by 27
“Bacterial cancer therapy (BCT) is the ancestor of modern immunotherapy, having origins in the late 19th Century, during which time U.S. physician William Coley used injections of Streptococcus to induce tumour regression in inoperable patients (Starnes, 1992).”
The Role of Surgical Pathology in Guiding Cancer Immunotherapy
Lovitch, S. B., & Rodig, S. J. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044125 · Cited by 20
Treating cancer with infection: a review on bacterial cancer therapy
Wong, S. L., & Slavcev, R. A. (2015) · Letters in Applied Microbiology · doi:10.1111/lam.12436 · Cited by 19
“It was not until the 20th century when Dr. W. Coley first systematically performed largescale treatments of cancer patients with live Streptococcus pyogenes and later, extracts of heat-killed Strep. pyogenes and Serratia marcescens (Coley 1910), now known as Coley’s toxins (Starnes 1992).”
BackgroundHaux, J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05369-7 · Cited by 19
Microbiota and Extracellular Vesicles in Anti-PD-1/PD-L1 Therapy
Mishra, S., Amatya, S. B., Salmi, S., Koivukangas, V., Karihtala, P., & Reunanen, J. (2022) · Cancers · doi:10.3390/cancers14205121 · Cited by 19
Preclinical Efficacy of Vascular Disrupting Agents in Non–Small-Cell Lung Cancer
Baguley, B. C. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.03.001 · Cited by 18
Microbiota and gastric cancer: from molecular mechanisms to therapeutic strategies
Chen, Z., Jin, D., Hu, J., Guan, D., Bai, Q., & Gou, Y. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1563061 · Cited by 23
“In the late 19th century, William Coley pioneered the use of a vaccine named “ Coley ’ s toxins, ” composed of two killed bacteria, Streptococcus pyogenes and Serratia marcescens , to treat various malignant tumors, resulting in promising therapeutic outcomes (Starnes, 1992).”
Ge, W., Song, S., Qi, X., Chen, F., Che, X., Sun, Y., Wang, J., Li, X., Liu, N., Wang, Q., et al. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.027942 · Cited by 21
Bullock, K. K., & Richmond, A. J. (2024) · Cancers · doi:10.3390/cancers16122189 · Cited by 22
“Created with BioRender.com (accessed on 9 May 2024).”
MethodObstacles to effective Toll-like receptor agonist therapy for hematologic malignancies
Spaner, D., Foley, R., Galipeau, J., & Bramson, J. L. (2008) · Oncogene · doi:10.1038/sj.onc.1210905 · Cited by 18
Tselikas, L., Dardenne, A., de Baère, T., Faron, M., Ammari, S., Farhane, S., Suzzoni, S., Danlos, F., Raoult, T., Susini, S., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.05.024 · Cited by 17
Inflammation, Infiltration, and Evasion—Tumor Promotion in the Aging Breast
Cruz-Reyes, N., & Radisky, D. C. (2023) · Cancers · doi:10.3390/cancers15061836 · Cited by 18
“Although “Coley’s toxins” were commercially available from 1899 and proved successful, their lack of a known mechanism of action and the high risk of infecting cancer patients with pathogenic bacteria led oncologists to prefer surgery and radiotherapy [13,14].”
BackgroundApplication of Nanotechnology in Therapeutic Cancer Vaccines
Guo, J., Tang, L., Li, K., Ma, Q., Luo, S., Cheng, R., & Liu, C. (2023) · Advanced NanoBiomed Research · doi:10.1002/anbr.202200122 · Cited by 15
Virtual screening of potential anticancer drugs based on microbial products
Pinto, G., Hendrikse, N. M., Štourač, J., Damborský, J., & Bednář, D. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.07.012 · Cited by 18
An Oral Commensal Associates with Disease: Chicken, Egg, or Red Herring?
Colucci, F. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.024 · Cited by 16
Li, D., & Rudloff, U. (2025) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2025.2504376 · Cited by 17
Targeting Intratumoral Bacteria for Cancer Treatment
Shi, J., Liang, J., Li, Y., Zhang, Z., Sun, J. X., He, Z., Luo, C., Qu, X., Che, X., & Zhang, S. (2025) · Small · doi:10.1002/smll.202505651 · Cited by 15
The multi-kingdom cancer microbiome
Dohlman, A. B., Pan, X., Zitvogel, L., & Iliev, I. D. (2025) · Nature Microbiology · doi:10.1038/s41564-025-02103-7 · Cited by 19
“Bacterial immunotherapy as a treatment for cancer has been attempted throughout history, dating from early antiquity to William Coley’s controversial experiments in the late nineteenth century 142,143 .”
Tumor Necrosis Factor: What Is in a Name?
Wang, X., Yang, C., Körner, H., & Ge, C. (2022) · Cancers · doi:10.3390/cancers14215270 · Cited by 14
“However, it also became clear that while mouse experiments that used high doses of human TNF were somewhat promising, using murine TNF in this context caused side effects that were comparable to inoculation with endotoxins, seemingly contradicting the earlier experience with Coley’s toxin [59] and thus preventing a qu…”
Enninga, E. A. L., Nevala, W. K., Holtan, S. G., & Markovic, S. N. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00424 · Cited by 14
Cancer Immunotherapy – The Target is Precisely on The Cancer and Also Not
Koo, S., Wang, W. W., & Toh, H. C. (2018) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v47n9p381 · Cited by 17
Chernov, A. N., Tsapieva, A., Alaverdian, D. A., Filatenkova, T. A., Galimova, E. S., Suvorova, M. A., Валерьевна, Ш. О., & Suvorov, A. N. (2022) · Molecules · doi:10.3390/molecules27020569 · Cited by 13
“Among them, Streptococcus pyogenes (group A streptococci or GAS) are promising agents due to oncolytic effects shown by “Coley’s toxin” [23] and OK-432 [24].”
BackgroundNeoantigen-driven personalized tumor therapy: An update from discovery to clinical application
Xie, N., Shen, G., Huang, C., & Zhu, H. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003708 · Cited by 15
Understanding the biology of ex vivo-expanded CD8 T cells for adoptive cell therapy: role of CD62L
Diaz-Montero, C. M., Zidan, A. A., Pallin, M., Anagnostopoulos, V. A., Salem, M. L., Wieder, E., Komanduri, K. V., Montero, A. J., & Lichtenheld, M. G. (2013) · Immunologic Research · doi:10.1007/s12026-013-8456-1 · Cited by 16
“Over 120 years ago, it began with the experimental injection of microbial toxins into sarcoma patients in New York [1].”
BackgroundZahedifard, Z., Mahmoodi, S., & Ghasemian, A. (2025) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2738 · Cited by 12
Combined bacterial and viral treatment: a novel anticancer strategy
Krzykawski, M. P. (2015) · Central European Journal of Immunology · doi:10.5114/ceji.2015.54601 · Cited by 12
Therapeutic strategies that selectively target and disrupt established tumor vasculature
Siemann, D. W. (2004) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2004.06.012 · Cited by 12
“Many early cancer therapies (eg, the deliberate induction of bacterial infections in patients who had cancer) undoubtedly relied, at least in part, on damage to the tumor blood vessel network that results from endotoxin-induced production of tumor necrosis factor (TNF)-a [13].”
BackgroundIntratumoral microorganisms in tumors of the digestive system
Xuan, M., Gu, X., Liu, Y., Li, Y., Li, Y., Huang, D., Li, J., & Xue, C. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01425-5 · Cited by 13
Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years
Koulouris, A., Tsagkaris, C., & Nikolaou, M. (2021) · Toxins · doi:10.3390/toxins13020149 · Cited by 14
Abscopal antitumor effect in a patient with melanoma and coronavirus disease 2019
Herrscher, H., Sauer, B., Truntzer, P., & Robert, C. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.003 · Cited by 10
Host–microbe cross talk in cancer therapy
Vanhoecke, B. W. A., & Stringer, A. M. (2015) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000133 · Cited by 13
Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future
Esin, E. (2017) · BioMed Research International · doi:10.1155/2017/1623679 · Cited by 11
“Based on the foresight of an immunological efficacy of Streptococcus pyogenes infection against tumor cells, he treated nearly 100 mixed type cancer patients with a 10% overall response rate [4, 5].”
BackgroundColey's vaccine and TNF therapy
Brouckaert, P., & Fiers, W. (1992) · Nature · doi:10.1038/358630a0 · Cited by 11
Checkpoint Inhibitor-Induced Autoimmune Diabetes: An Autoinflammatory Disease
Quandt, Z., Perdigoto, A. L., Anderson, M. S., & Herold, K. C. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041603 · Cited by 15
Tang, Z., Zha, L., Liang, R., & Li, T. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01778-7 · Cited by 12
“In the 1890 s, Dr. William B. Coley treated inoperable sarcomas with a mixture of heat-killed Streptococcus pyogenes and Serratia marcescens (Coley’s toxins), achieving notable clinical successes [23].”
Effects and mechanisms of Helicobacter pylori on cancers development and immunotherapy
Zhong, X., Zheng, H., Zhao, S., Wang, Z., Su, Y., Zhong, K., Wang, M., & Shi, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1469096 · Cited by 12
Anticancer potential of tumor vascular disrupting agents: review of the latest clinical evidence
Baguley, B. C., & McKeage, M. J. (2012) · Clinical Investigation · doi:10.4155/cli.12.98 · Cited by 10
Immunotherapy in Acute Leukemia
Leung, W. H. (2008) · Seminars in Hematology · doi:10.1053/j.seminhematol.2008.09.004 · Cited by 11
“Klin Padiatr 2005 Nov–Dec;217(6):351–6.”
Baliou, S., Adamaki, M., Spandidos, D. A., Kyriakopoulos, A. M., Christodoulou, I., & Zoumpourlis, V. C. (2018) · World Academy of Sciences Journal · doi:10.3892/wasj.2018.6 · Cited by 11
Perspectives on Microglia-Based Immune Therapies Against Glioblastoma
Rivera, M., Bander, E. D., & Cisse, B. (2021) · World Neurosurgery · doi:10.1016/j.wneu.2021.06.127 · Cited by 10
Tumour-infiltrating lymphocytes in cancer: implications for the diagnostic pathologist
Simonson, W. T. N., & Allison, K. H. (2010) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2010.10.006 · Cited by 10
Ma, X., Song, Y., Zhang, K., Shang, L., Gao, Y., Zhang, W., Xue, X., Jia, H., Geng, J., Zhou, W. J., et al. (2015) · Scientific Reports · doi:10.1038/srep09918 · Cited by 10
The emerging prospects of circular RNA in tumor immunity
Meng, L., Ding, P., Liu, S., Li, Z., Sang, M., & Shan, B. (2020) · Annals of Translational Medicine · doi:10.21037/atm-19-4751 · Cited by 12
“The earliest study on the response of the immune system to tumors used Coley’s toxins to trigger an immune response and treat a variety of inoperable cancers (15).”
BackgroundYang, X., Kang, N., Toyofuku, W. M., & Scott, M. D. (2018) · Immunobiology · doi:10.1016/j.imbio.2018.12.003 · Cited by 10
Li, M., Xu, T., Zhang, Z., Xue, X., Zhang, C., Qin, X., Li, W., Hao, Q., Zhang, W., & Zhang, Y. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02153.x · Cited by 9
Hull, R., Lolas, G., Makrogkikas, S., Jensen, L. D., Syrigos, K. N., Evangelou, G., Padayachy, L. C., Egbor, C., Mehrotra, R., Makhafola, T. J., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9102129 · Cited by 8
“We now know, erysipelas causes an inflammatory reaction that most probably are negating the sarcoma [4,5].”
BackgroundIntratumoral cancer immunotherapy exploiting anti-viral immunity
Kadowaki, N. (2021) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.21023 · Cited by 8
Could intratumoural microbiota be key to unlocking treatment responses in hepatocellular carcinoma?
Yu, K. L., & Shen, S. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115195 · Cited by 8
A proposal for a simple and inexpensive therapeutic cancer vaccine
Fahrer, A. M. (2011) · Immunology and Cell Biology · doi:10.1038/icb.2011.42 · Cited by 7
Cytokine Biopharmaceuticals with “Activity-on-Demand” for Cancer Therapy
Rotta, G., Puca, E., Cazzamalli, S., Neri, D., & Plaza, S. D. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00187 · Cited by 7
Engineering approaches for innate immune-mediated tumor microenvironment remodeling
Kane, G. I., Lusi, C. F., Brassil, M. L., & Atukorale, P. U. (2023) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2023.100406 · Cited by 11
Cleton-Jansen, A., Buddingh, E. P., & Lankester, A. C. (2012) · OncoImmunology · doi:10.4161/onci.1.2.18345 · Cited by 6
“The few known permanent responses to Coley’s toxins in carcinoma were in those cases of mesodermal origin.(2) Are sarcomas and other tumors of mesodermal origin more immunogenic than carcinomas? Or do immune cells have an effect that is different between sarcomas and carcinomas? The tumor promoting effect of macrophag…”
Suzuki, A., Abe, S., Koyama, K., Suzuki, S., Nagao, M., Kobayashi, M., Nomura, J., Tsutsumi, T., Takeda, T., Oka, Y., et al. (2021) · Internal Medicine · doi:10.2169/internalmedicine.5820-20 · Cited by 7
Perspectives on microbes as oncogenic infectious agents and implications for breast cancer
Nackerdien, Z. E. (2008) · Medical Hypotheses · doi:10.1016/j.mehy.2008.02.016 · Cited by 6
“Because of the immunological dependence of endotoxin therapy and the fact that patients entering clinical trials had previously been subjected to radiotherapy and/or chemotherapy (with known immunological side-effects), the outcomes of later cancer vaccine studies proved disappointing and this approach was abandoned […”
BackgroundYoshida, J., Takamura, S., Suzuki, S., & Nishio, M. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.182 · Cited by 6
Dooley, S. W., Gong, M. F., Carlson, L., Frear, A. J., Mandell, J. B., Zheng, A., Bhogal, S. S., Schoedel, K. E., & Weiss, K. R. (2023) · Annals of Joint · doi:10.21037/aoj-22-41 · Cited by 5
Advances in cancer immunotherapy: The role of super NK and super CAR-T cells
Almohaimeed, H. M., Chowdhury, A., Sarkar, S., Almars, A. I., Tounsi, W. A., Singh, A., Krithiga, T., Ray, S., & Uti, D. E. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115074 · Cited by 7
Clinical pharmacologic aspects of immune checkpoint inhibitors in cancer therapy
Kim, K., & Jung, H. (2016) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2016.24.1.7 · Cited by 5
“Introduction Coley had reported the shrinkage of sarcoma after the bacterial infection erysipelas in the late 19th century.[1] The low rate of response portrayed two important issues: the potential of harnessing the immune system against cancer and the importance of selecting the right patients.”
BackgroundLint, S. V., Nuffel, A. M. T. V., Wilgenhof, S., Benteyn, D., Pen, J. J., Escors, D., Bonehill, A., Neyns, B., Thielemans, K., & Breckpot, K. (2013) · Ghent University Academic Bibliography (Ghent University) · Cited by 7
Суворова, М. А., Tsapieva, A., Bak, E. G., Черешнев, В. А., Kisseleva, E. P., Suvorov, A. N., & Arumugam, M. (2017) · Genome Announcements · doi:10.1128/genomea.00939-17 · Cited by 5
“It has also been used for bacteriolytic cancer therapy starting with “Coley’s toxins” (2) and followed by OK-432 (picibanil) (3), but the mechanisms behind its antitumor activity are unknown.”
MethodRecent Developments in Patented DC-Based Immunotherapy for Various Malignancies
Harada, Y., & Yonemitsu, Y. (2011) · Recent Patents on Regenerative Medicine · doi:10.2174/2210296511101010072 · Cited by 5
Zhang, J., Wei, Z., & Fan, G. (2025) · Foods · doi:10.3390/foods14173040 · Cited by 5
“BCT has a long history of application dating back to late 19th century, during which time Streptococcus was used to induce tumor regression in operable patients [74].”
Breaking the Mold: Trailblazing Melanoma Therapy Beyond Checkpoint Through Innovative Approaches
Kidwai, N., Chen, M. F., Postow, M. A., Hassel, J. C., & Callahan, M. K. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432462 · Cited by 5
Immunotherapy Exploiting the Versatility of Dendritic Cells
Kadowaki, N. (2003) · Therapeutic Apheresis and Dialysis · doi:10.1046/j.1526-0968.2003.00048.x · Cited by 4
“Coley’s achievement (1) may imply this basic scheme.”
BackgroundMinard‐Colin, V. (2016) · Revue d Oncologie Hématologie Pédiatrique · doi:10.1016/j.oncohp.2016.01.002 · Cited by 4
Chopra, A. S., Liu, X., & Liu, H. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803892-5.00013-9 · Cited by 5
Merchant, M., Hebert, M., Salvador, A. C., Berken, J., Boverie, T., & White, M. E. (2024) · Animals · doi:10.3390/ani14060965 · Cited by 5
Vianna, P., Mendes, M. F. A., Bragatte, M. A. D. S., Ferreira, P. S., Salzano, F. M., Bonamino, M., & Vieira, G. F. (2019) · Cells · doi:10.3390/cells8121488 · Cited by 6
A Concise History of the Discovery of Mammalian Nitric Oxide (Nitrogen Monoxide) Biogenesis
Lancaster, J. R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804273-1.00001-6 · Cited by 4
Near Term Prospects for Broad Spectrum Amelioration of Cancer
Cui, Z. (2010) · Springer eBooks · doi:10.1007/978-90-481-3999-6_9 · Cited by 4
“LPS was eventually dismissed as a cancer treatment after disappointing results were obtained in several large clinical trials ( Starnes 1992; Wiemann and Starnes 1994; Richardson et al. 1999; Bickels et al. 2002; Zacharski and Sukhatme 2005; Tsung and Norton 2006).”
ResultIntra-tumoral microbiota: Key modulators of tumor immunity and therapeutic potential
He, J., Tan, H. Z., Qiu, Y., Dan, Y., Wan, Q., Li, L., Wu, J., Song, Q., Chen, H., & Xu, B. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101963 · Cited by 5
“3,205,206 Clinical studies indicate that antibiotic eradication of specific microorganisms may prevent tumorigenesis and enhance cancer therapies.”
Zhao, F., An, R., Yu, S., Ma, Y., Liu, W., 盛彩霞, Xie, X., & Zhang, J. (2026) · Clinical and Translational Medicine · doi:10.1002/ctm2.70704 · Cited by 4
Zhu, L., Jiang, N., & Zhang, Z. (2026) · Immunity & Inflammation · doi:10.1007/s44466-026-00043-3 · Cited by 3
“Although the concept of “activating the host immune system to treat cancer” was proposed more than a century ago [10, 11], only in recent decades have advances in basic and clinical research enabled immune checkpoint blockade (ICB) and adoptive cell therapies (ACT) to enter clinical practice and…”
Using machine learning and RNA to enhance the efficacy of anti-tumor immunotherapy
Wei, Y., & Su, Y. (2022) · Evolutionary Intelligence · doi:10.1007/s12065-022-00781-4 · Cited by 3
The effect of bacteria on tumor metastasis
Yu, J., Meng, Q., Chen, Y., Ji, F., & Wang, L. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-1358 · Cited by 2
Metadata
- Authors
- Starnes, C. O.
- Affiliations
- Amgen (United States) (US)
- Corresponding author
- Starnes, Charlie O.
- Venue
- Nature
- Published
- 1992-05
- Volume
- 357
- Issue
- 6373
- Pages
- 11-12
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2005179058
- Cited by
- 284
- References
- 6
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 34 · 2023: 14 · 2022: 14 · 2021: 19 · 2020: 17 · 2019: 9 · 2018: 11 · 2017: 12 · 2016: 7 · 2015: 15 · 2014: 8 · 2013: 9 · 2012: 7
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
- Keywords
- Coley's toxins, TNF-α, cancer therapy, patient selection, treatment efficacy
- MeSH terms
- Bacterial Vaccines, Humans, Sarcoma, Soft Tissue Neoplasms, Tumor Necrosis Factor-alpha, History, 19th Century, History, 20th Century
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.